Search results
Results from the WOW.Com Content Network
Typical chemotherapy is six cycles of intraperitoneally-delivered platinum-base adjuvant chemotherapy with agents such as carboplatin. [39] Measurements of blood CA125 levels are used to determine patient response to the treatment. Between 20% and 30% of patients relapse within six months of treatment. [52]
Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments.
Cancer treatment needs to be selected to do least harm to both the woman and her embryo/fetus. In some cases a therapeutic abortion may be recommended. Radiation therapy is out of the question, and chemotherapy always poses the risk of miscarriage and congenital malformations. [63] Little is known about the effects of medications on the child.
Another important strategy developed from this — if the tumour burden could be reduced first by surgery, then chemotherapy may be able to clear away any remaining malignant cells, even if it would not have been potent enough to destroy the tumor in its entirety. This approach was termed "adjuvant therapy".
Some breast cancer patients, particularly those with high-risk features such as a large number of involved lymph nodes, aggressive tumor biology, or those who do not respond adequately to standard adjuvant therapy, may be considered for HDC. However, the role of HDC in breast cancer is more controversial and is generally reserved for the ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
At the end of the study, the responders hadn't reached the 18-month RFS endpoint, meaning that their cancer hadn't recurred in the 18 months following treatment, while the non-responders had a median RFS of 13.4 months. The authors concluded that, given the preliminary evidence of efficacy and safety, an international phase 2 trial was imminent.
The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard ...